Natera, Inc. $NTRA Shares Acquired by National Pension Service

National Pension Service increased its position in Natera, Inc. (NASDAQ:NTRA) by 2,249.4% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 217,837 shares of the medical research company’s stock after purchasing an additional 208,565 shares during the period. National Pension Service’s holdings in Natera were worth $49,904,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of NTRA. Horizon Investments LLC acquired a new position in Natera in the third quarter worth about $32,000. Flagship Harbor Advisors LLC acquired a new position in Natera in the fourth quarter valued at approximately $41,000. Sound Income Strategies LLC boosted its stake in Natera by 20.0% in the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after acquiring an additional 45 shares during the period. TD Waterhouse Canada Inc. acquired a new position in Natera in the fourth quarter valued at approximately $62,000. Finally, AXS Investments LLC acquired a new position in Natera in the third quarter valued at approximately $69,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced a new collaboration with Diakonos Oncology to use Signatera in a Phase I/II study for refractory melanoma, expanding a key cancer-testing product into another clinical use case and reinforcing its oncology growth story. Article Title
• Positive Sentiment: Canaccord raised its price target on Natera to $250 from $200, signaling stronger confidence in the company’s outlook and helping fuel bullish sentiment. Article Title
• Positive Sentiment: Natera is also drawing attention from investors after commentary calling it a favorite stock idea for the rest of 2026, which adds to the momentum around the name. Article Title

Analyst Ratings Changes

NTRA has been the subject of a number of research reports. Wells Fargo & Company lifted their target price on Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Morgan Stanley decreased their target price on Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. JPMorgan Chase & Co. lifted their target price on Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Evercore restated an “outperform” rating and issued a $270.00 target price on shares of Natera in a research note on Friday, May 8th. Finally, Wall Street Zen downgraded Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $256.60.

Natera Stock Performance

NTRA opened at $223.37 on Monday. The business’s 50 day moving average is $202.37 and its 200-day moving average is $215.75. The stock has a market cap of $31.99 billion, a PE ratio of -137.04 and a beta of 1.56. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $256.36.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. The company had revenue of $665.50 million for the quarter, compared to analysts’ expectations of $600.68 million. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.During the same quarter in the previous year, the company posted ($0.41) earnings per share. As a group, analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Michael Burkes Brophy sold 482 shares of Natera stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $210.49, for a total transaction of $101,456.18. Following the sale, the chief financial officer owned 57,496 shares of the company’s stock, valued at approximately $12,102,333.04. The trade was a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 902 shares of Natera stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $206.16, for a total value of $185,956.32. Following the sale, the chief executive officer directly owned 149,867 shares in the company, valued at approximately $30,896,580.72. This trade represents a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 34,406 shares of company stock worth $6,984,955. 5.05% of the stock is currently owned by corporate insiders.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.